Abstract
In 2018, the world of functional mitral regurgitation changed with the presentation of two trials - Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation (MITRA-FR) and Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT). The trials, which seemed to point in two different directions, raised significant questions for the field. This article looks at the differences in effective regurgitant area, guideline-directed medical therapy, patient selection, technical clues and other reasons why the trials had similar aims but very different findings.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 45-47 |
| Number of pages | 3 |
| Journal | Interventional Cardiology Review |
| Volume | 14 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
Keywords
- COAPT
- Congestive heart failure
- Effective orifice area
- Functional mitral regurgitation
- Heart failure
- MITRA-FR
- Mitral regurgitation
- Optimal medical therapy
- Secondary mitral regurgitation
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Why did coapt win while mitra-FR failed? Defining the appropriate patient population for MitraClip. / Atianzar, Kimberly; Zhang, Ming; Newhart, Zachary; Gafoor, Sameer.
In: Interventional Cardiology Review, Vol. 14, No. 1, 01.01.2019, p. 45-47.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Why did coapt win while mitra-FR failed? Defining the appropriate patient population for MitraClip
AU - Atianzar, Kimberly
AU - Zhang, Ming
AU - Newhart, Zachary
AU - Gafoor, Sameer
PY - 2019/1/1
Y1 - 2019/1/1
N2 - In 2018, the world of functional mitral regurgitation changed with the presentation of two trials - Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation (MITRA-FR) and Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT). The trials, which seemed to point in two different directions, raised significant questions for the field. This article looks at the differences in effective regurgitant area, guideline-directed medical therapy, patient selection, technical clues and other reasons why the trials had similar aims but very different findings.
AB - In 2018, the world of functional mitral regurgitation changed with the presentation of two trials - Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation (MITRA-FR) and Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT). The trials, which seemed to point in two different directions, raised significant questions for the field. This article looks at the differences in effective regurgitant area, guideline-directed medical therapy, patient selection, technical clues and other reasons why the trials had similar aims but very different findings.
KW - COAPT
KW - Congestive heart failure
KW - Effective orifice area
KW - Functional mitral regurgitation
KW - Heart failure
KW - MITRA-FR
KW - Mitral regurgitation
KW - Optimal medical therapy
KW - Secondary mitral regurgitation
UR - http://www.scopus.com/inward/record.url?scp=85072266158&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072266158&partnerID=8YFLogxK
U2 - 10.15420/icr.2018.40.1
DO - 10.15420/icr.2018.40.1
M3 - Article
AN - SCOPUS:85072266158
VL - 14
SP - 45
EP - 47
JO - Interventional Cardiology
JF - Interventional Cardiology
SN - 1755-5302
IS - 1
ER -